ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CABA
LXEO (33) LCTX (20) FATE (35) IPSC (18) ⌘ Pro Terminal →

Cabaletta Bio Inc. (CABA) — RQD Stock Rating Cockpit

$1.43 -5.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.41

Cabaletta Bio Inc. (CABA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $256.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CABA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CABA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cabaletta Bio Inc. (NASDAQ: CABA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.43 (-5.30% 1D, market cap $256.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CABA ranks #681 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CABA compare to LXEO and LCTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CABA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $257.6M) and LCTX (Lineage Cell Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M). Among the 5-stock peer group, CABA leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CABA?
▼

Per CABA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759138), Cabaletta Bio Inc. generated $482.3M in revenue (+37.6% YoY), -$167.9M in net income, and -$132.3M in free cash flow against $165.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.41 (-1.14%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE CABA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CABA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY CABA SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 38.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$1.69-4.7% Next Q
Q2 (-2Q)
38
Grade E$1.61-9.3% Next Q
Q3 (-1Q)
36
Grade E$1.46-2.1% Next Q
Current
33
Grade E$1.43-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CABA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CABA currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.24) and Max Pain ($1.50) forces dealer call-delta covering toward $4.44.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CABA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CABA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
38.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE4% OF RANGE
L: $1$1.43H: $4
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CABA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

8/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like CABA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CABA)

  • ✓Walkthrough of CABA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CABA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.66%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.58H $1.58L $1.43C $1.43VOL 3.76M
RES: $3.51SUP: $1.24SMA50: $2.24SMA200: $2.85
$4.43$3.59$2.75$1.90$1.06RES $3.51SUP $1.24$1.432026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CABA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CABA Butterfly Map → + Track CABA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CABA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CABA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CABA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CABA)

Health Care Rank #681 of 1015 ⚔️ LXEO vs CABA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CABA vs. LXEO, LCTX, FATE, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cabaletta Bio Inc. (CABA) ranks #681 by composite RQD confidence (33/100, grade E) and #536 by equity capitalization ($256.0M). Within this direct 5-issuer industry benchmark cohort, CABA leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with CABA at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CABA ACTIVE
Cabaletta Bio Inc.
E 33/100 — — -35.0% -5.30% $256.0M Benchmark Subject
LXEO
Lexeo Therapeutics Inc.
E 33/100 — — -35.0% -2.55% $257.6M /lxeo-vs-caba →
LCTX
Lineage Cell Therapeutics Inc.
E 20/100 — — -35.0% +1.00% $252.9M /lctx-vs-caba →
FATE
Fate Therapeutics Inc.
D- 35/100 — — -35.0% -3.36% $249.2M /fate-vs-caba →
IPSC
Century Therapeutics Inc.
E 18/100 — — -14.1% +0.68% $266.2M /ipsc-vs-caba →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001759138 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cabaletta Bio Inc. (CABA) reported GAAP revenue of $482.3M (+37.6% vs. FY2024 revenue of $350.4M , and +130.7% cumulative change since FY2023) , GAAP net income of -$167.9M, operating cash flow of -$131.1M, and free cash flow of -$132.3M (-46.3% YoY). On the balance sheet, CABA closed FY2025 with $165.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $482.3M -$167.9M -$131.1M -$132.3M $165.1M —
FY2024 (FY) 2024-12-31 $350.4M -$115.9M -$88.2M -$90.4M $185.0M —
FY2023 (FY) 2023-12-31 $209.0M -$67.7M -$53.5M -$53.5M — —

3. CABA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CABA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cabaletta Bio Inc. (NASDAQ: CABA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.43 (-5.30% 1D, market cap $256.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CABA ranks #681 in composite RQD confidence.

How does CABA compare to LXEO and LCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CABA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $257.6M) and LCTX (Lineage Cell Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M). Among the 5-stock peer group, CABA leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CABA?

Per CABA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759138), Cabaletta Bio Inc. generated $482.3M in revenue (+37.6% YoY), -$167.9M in net income, and -$132.3M in free cash flow against $165.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CABA trading relative to its 50-day, 200-day, and 52-week technical levels?

CABA last traded at $1.43 (-5.30% on volume of 5,685,606 shares), positioning the stock -36.16% below its 50-day simple moving average ($2.24) and -49.82% below its 200-day simple moving average ($2.85). Across its 52-week range of $1.32 to $4.23, CABA sits at the 3.8% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).

Direct Sub-Reports: CABA RQD Cockpit CABA 12M Forecast CABA Earnings & Move CABA Dividends & DRIP CABA Insiders & 13F CABA Whale Options CABA Profit Sankey CABA News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

CABA — Cabaletta Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cabaletta Bio Inc. (CABA) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.43 (-5.30% 1D, market capitalization $256.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cabaletta Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $0.3B. Reported revenue for FY 2025 is —, consistent with the absence of revenue in the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cabaletta Bio Inc. (CABA) reported $482.3M in annual revenue (up from $350.4M in FY2024, +37.6% YoY) and -$167.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($209.0M revenue, -$67.7M net income) through FY2025, CABA scaled operating cash flow to -$131.1M and free cash flow to -$132.3M, backed by $165.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.32 – $4.23 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain: NONE; butterfly links: none; proprietary signals: none. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The sector classification (Health Care / Biological Products) and beta of 1.

  • Key Question #1: Can CABA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $482.3M and free cash flow of -$132.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CABA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CABA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cabaletta Bio Inc. (CABA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CABA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CABA Bull vs. Bear Conversation Board — What's Your Call at $1.43?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CABA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CABA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $1.80 (+19.2%)
📌 Pinned Debate

The stock trades at $1.59, near the low end of its $1.32 to $4.23 52-week range, and the Forensic Balance Sheet pillar (10/20, Altman Z

Don't sleep on CABA's setup in Health Care. The stock trades at $1.59, near the low end of its $1.32 to $4.23 52-week range, and the Forensic Balance Sheet pillar (10/20, Altman Z 2.5) is the strongest of the five RQD pillars.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (33/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — CABA's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.28 (-15.2%)
Spot @ $1.51

Reported operating losses widened from -$74.7M in FY 2023 to -$172.2M in FY 2025 with zero revenue, ROIC at -35%, and FCF yield at 0%,

Here is the bear case nobody on the bull side wants to address on CABA: Reported operating losses widened from -$74.7M in FY 2023 to -$172.2M in FY 2025 with zero revenue, ROIC at -35%, and FCF yield at 0%, while cash fell from $164.0M to $83.0M.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%